VIA Pharmaceuticals Liabilities 2024

VIA Pharmaceuticals Aktienanalyse

What does VIA Pharmaceuticals do?

VIA Pharmaceuticals is a biopharmaceutical company specializing in the development of drugs for the treatment of cardiovascular diseases. The company was founded in 1999 in San Francisco. The vision of VIA Pharmaceuticals from the beginning was to develop more innovative therapies for the treatment of cardiovascular diseases that are more effective and have fewer side effects compared to existing treatment options. The company focuses on the discovery and exploration of new active substances and technologies that target the causes of cardiovascular diseases. VIA Pharmaceuticals' business model is based on collaboration with other biopharmaceutical companies and research institutes. For example, the company collaborates with the Cleveland Clinic and the University of California to advance the development of new drugs. Collaboration with investors and financial institutions also plays an important role in VIA Pharmaceuticals' business model. The various divisions of VIA Pharmaceuticals specialize in the treatment of cardiovascular diseases. In particular, drugs for the treatment of atherosclerosis, one of the main causes of cardiovascular diseases, are being developed. VIA Pharmaceuticals' research focuses on reducing inflammation and blood lipids. The products of VIA Pharmaceuticals are currently still in clinical development. One of the most promising products of the company is VIA-2291, a drug for the treatment of atherosclerosis. The drug specifically targets inflammation in blood vessels, reducing the risk of plaques and thrombosis. VIA-2291 has already shown promising results in clinical trials and is currently in phase 3 of clinical development. Other products of VIA Pharmaceuticals are in various stages of clinical development. Overall, VIA Pharmaceuticals is an innovative biopharmaceutical company specializing in the development of drugs for the treatment of cardiovascular diseases. The company relies on collaboration with other research institutes and biotech companies. The products of VIA Pharmaceuticals are currently still in clinical development but show promising results and could contribute to making the treatment of cardiovascular diseases more effective and with fewer side effects in the future. VIA Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing VIA Pharmaceuticals's Liabilities

VIA Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating VIA Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing VIA Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

VIA Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in VIA Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about VIA Pharmaceuticals stock

What is the level of liabilities of VIA Pharmaceuticals this year?

VIA Pharmaceuticals has a debt balance of 0 USD this year.

What were the liabilities of VIA Pharmaceuticals compared to the previous year?

The liabilities of VIA Pharmaceuticals have increased by 0% dropped compared to the previous year.

What are the consequences of high debt for investors of VIA Pharmaceuticals?

High liabilities can pose a risk for investors of VIA Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in VIA Pharmaceuticals?

Low liabilities mean that VIA Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of VIA Pharmaceuticals affect the company?

An increase in liabilities of VIA Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of VIA Pharmaceuticals affect the company?

A decrease in the liabilities of VIA Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of VIA Pharmaceuticals?

Some factors that can influence the liabilities of VIA Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of VIA Pharmaceuticals so important for investors?

The liabilities of VIA Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can VIA Pharmaceuticals take to modify the liabilities?

To change its liabilities, VIA Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does VIA Pharmaceuticals pay?

Over the past 12 months, VIA Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, VIA Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of VIA Pharmaceuticals?

The current dividend yield of VIA Pharmaceuticals is .

When does VIA Pharmaceuticals pay dividends?

VIA Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of VIA Pharmaceuticals?

VIA Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of VIA Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is VIA Pharmaceuticals located?

VIA Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von VIA Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of VIA Pharmaceuticals from 10/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.

When did VIA Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/5/2024.

What was the dividend of VIA Pharmaceuticals in the year 2023?

In the year 2023, VIA Pharmaceuticals distributed 0 USD as dividends.

In which currency does VIA Pharmaceuticals pay out the dividend?

The dividends of VIA Pharmaceuticals are distributed in USD.